Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer (Q82847589)
Jump to navigation
Jump to search
scientific article published on 01 January 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer |
scientific article published on 01 January 2012 |
Statements
Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer (English)
Diego J Bedoya
Nicholas Mitsiades
1 January 2012